Pennsylvania Approved Study of PANDAS and PANS
The state aims to evaluate treatment coverage for children after a local family faced high costs for PANDAS care.
Updated on Sept. 22, 2026 in Autism
In summer 2026, Pennsylvania lawmakers passed a resolution directing the Joint State Government Commission to study PANDAS and PANS. This legislative move aims to inform future insurance coverage policies for conditions that impact an estimated 1 in 200 children.
Why it matters
The study addresses significant hurdles for families, such as the Janeda family, whose daughter faced denied insurance coverage for an $11,000 monthly treatment. Legislative findings could lead to new requirements for insurance providers regarding the coverage of PANDAS and PANS diagnostics and therapies.
The resolution tasks the Joint State Government Commission with an 18-month review of existing medical literature and current state policies. This commission will assess how PANDAS, which affects approximately 1 in 200 children, fits into the current regulatory and insurance landscape.
The players
Macy Janeda
A 10-year-old patient who developed symptoms of PANDAS following a strep infection.
Jill Cooper
A State Representative who presented the legislative resolution to the Pennsylvania House.
Joint State Government Commission
A non-partisan state agency tasked with researching policy issues to inform future Pennsylvania legislation.
The details
PANDAS and PANS are conditions where children, such as a 10-year-old local patient, can develop sudden onset symptoms like tics and OCD following infections. Some patients are prescribed intravenous immunoglobulin (IVIG) therapy to manage these symptoms. Currently, families often face coverage denials from insurance companies, forcing some to seek out-of-network providers to secure a diagnosis and necessary medical treatments.
Timeline
March 2026: The patient developed symptoms following a strep infection.
Summer 2026: The Pennsylvania House passed the legislative resolution.
Next 18 months: The Joint State Government Commission will conduct its study.
Health Landscape
This study is a direct response to the lack of standardized health insurance coverage for PANDAS and PANS in Pennsylvania. It aligns with broader efforts to evaluate how medical systems account for complex, infection-triggered neuro-psychiatric conditions.
Families struggling with the costs of complex autoimmune or neuro-psychiatric diagnoses should discuss coverage gaps with their insurance providers and primary care physicians. Keeping detailed records of your clinician's recommended treatments is a vital step while these policy discussions evolve.
The takeaway
This study aims to address the significant financial burden placed on families seeking treatment for PANDAS. Residents should track these legislative updates and consider discussing with a physician whether current care plans for sudden-onset symptoms align with available evidence-based interventions.
What happens next
The Joint State Government Commission is expected to report its research findings and legislative suggestions in approximately 18 months.
Further reading
For broader context on current clinical research and diagnostic support for neurodevelopmental conditions, visit Autism.
Source note: This article includes information reported by CBS News.
